TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01166113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Cyclophosphamide, Prednisone
Description: Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d
Study: NCT05872646

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical assessment
Description: clinical staging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical assessment
Description: clinical staging
Study: NCT03495310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
Study: NCT01760538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: received usual medical care after heart transplantation
Study: NCT03325296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 124249
Description: Ointment containing LEO 124249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Ointment without active ingredients
Study: NCT02244840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic bidet
Description: commercial electronic bidet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sitz bath
Description: Conventional sitz bath
Study: NCT01377610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol
Description: dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol
Description: dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
Study: NCT02043912

Intervention type: DRUG
Intervention: Haloperidol
Study: NCT04117490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epiitalis
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epiitalis
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epiitalis
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).
Study: NCT03321864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound scan of prostate
Description: Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
Study: NCT04403152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-operative rehabilitation
Description: Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative mobilization
Description: Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
Study: NCT02928302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVU CL screening
Description: Transvaginal ultrasound cervical length screening
Study: NCT03556592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 1x 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2x 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 1x 20 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 1x 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: 1 mL of 2 mg/mL oral solution/syrup
Study: NCT02050347

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 2
Description: Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 2
Description: Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 1
Description: Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 1
Description: Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg
Study: NCT02689466

Intervention type: DRUG
Intervention: [18F]FP-TZTP
Description: radioligand

Intervention type: DRUG
Intervention: [18F]FP-TZTP
Description: radioligand
Study: NCT04414592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
Study: NCT03554941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noise stimulation
Description: noise stimulation
Study: NCT02091531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Study: NCT00945529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide (iNO)
Description: Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
Study: NCT04023591

Intervention type: PROCEDURE
Intervention: Surgery/Occupational Therapy
Description: Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
Study: NCT01080521

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Ancillary studies
Study: NCT03926533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
Study: NCT00726037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
Study: NCT02392390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Dynamic Phototherapy (TDP)
Description: Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvixia cream
Study: NCT03401944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPN

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01080521

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06397014

Intervention type: PROCEDURE
Intervention: D-type stoma lateral hernia repair
Description: underwent D-type stoma lateral hernia repair

Intervention type: PROCEDURE
Intervention: D-type stoma lateral hernia repair
Description: underwent D-type stoma lateral hernia repair
Study: NCT02406976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1 -Exercise
Description: 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G2- Exercise and Lifestyle
Description: Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G3- Control
Description: Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G3- Control
Description: Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G3- Control
Description: Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
Study: NCT04567706

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study: NCT02668900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support
Description: The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
Study: NCT02200003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention bias modification for anxiety

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: attention bias modification for anxiety
Study: NCT00562263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Dietary modification and regular physical activity
Study: NCT03155100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
Study: NCT02266654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids
Description: Normal Saline 0.9%
Study: NCT04267848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study: NCT02896491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure with non-ionizing electromagnetic fields
Description: In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Exposure with non-ionizing electromagnetic fields
Description: In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure with non-ionizing electromagnetic fields
Description: In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
Study: NCT00522418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Simulation (VNS) Therapy
Description: VNS Therapy + Best Medical Practice including anti-epileptic drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Practive
Description: Best Medical Practice including anti-Epileptic Drugs
Study: NCT03537365

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum (BC) / intervention group
Description: Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FM85 / control group
Description: Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed.
Study: NCT00653848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel 75 mg/square meter i.v. every third week, six cycles
Study: NCT02954406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet
Study: NCT04267848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT04441021

Intervention type: OTHER
Intervention: Penicillin Allergy Risk Stratification and Evaluation
Description: This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
Study: NCT04010357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib,
Description: Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
Study: NCT03825315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI 80 U
Description: DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI 120 U
Description: DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
Study: NCT02266654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids
Description: Normal Saline 0.9%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Notification
Description: Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
Study: NCT04267848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT01874964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Methadone Maintenance
Description: Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage to methadone maintenance
Description: Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
Study: NCT02620449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will be fed a low-additive diet as the primary intervention
Study: NCT04267848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT02954406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet